NervGen Pharma Balance Sheet Health

Financial Health criteria checks 5/6

NervGen Pharma has a total shareholder equity of CA$9.2M and total debt of CA$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are CA$22.5M and CA$13.3M respectively.

Key information

Debt to equity ratio

CA$0

Debt

Interest coverage ratio	n/a
Cash	CA$21.01m
Equity	CA$9.18m
Total liabilities	CA$13.28m
Total assets	CA$22.46m

Recent financial health updates

No updates

Recent updates

Financial Position Analysis

Short Term Liabilities: NGEN.F's short term assets (CA$21.9M) exceed its short term liabilities (CA$13.2M).

Long Term Liabilities: NGEN.F's short term assets (CA$21.9M) exceed its long term liabilities (CA$33.2K).

Debt to Equity History and Analysis

Debt Level: NGEN.F is debt free.

Reducing Debt: NGEN.F has not had any debt for past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: NGEN.F has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: NGEN.F has less than a year of cash runway if free cash flow continues to reduce at historical rates of 23.7% each year

NervGen Pharma Balance Sheet Health

Financial Health criteria checks 5/6

Key information

Recent financial health updates

Recent updates

NervGen Pharma Corp. Appoints Neil Klompas to Board of Directors

NervGen Pharma Corp. Approves Board and Audit Committee Elections

NervGen Pharma Corp., Annual General Meeting, Jun 04, 2024

NervGen Pharma Corp. Receives Fast Track Designation for NVG-291 for the Treatment of Individuals with Spinal Cord Injury

Nervgen Pharma Appoints John Ruffolo to Board of Directors

NervGen Pharma Corp. Announces First Subject Dosed in Landmark Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury

NervGen Pharma Announces Completion of Dosing of All Subjects in Phase 1 Clinical Trial of Proprietary Drug Candidate NVG-291

Nervgen Pharma Corp. Receives FDA Authorization to Expand Enrollment of Males and Premenopausal Females in Phase 1 Clinical Trial of NervGen's NVG-291

NervGen Pharma Corp. Receives Up to $1.5 Million US Department of Defense Funding to Evaluate NervGen's NVG-291-R for Peripheral Nerve Injury

NervGen Pharma Corp. Announces Executive Changes

NervGen Pharma Corp., Annual General Meeting, Sep 28, 2022

NervGen Pharma Corp. announced that it has received $15.225 million in funding from PFP Biosciences Holdings

NervGen Pharma Corp. Appoints Adam Rogers to its Board of Directors

NervGen Pharma Corp. announced that it expects to receive $15.225 million in funding

Nervgen Pharma Corp. Receives Approval from the Safety Review Committee to Advance to the Third and Highest Dose Cohort in the Multiple Ascending Dose Portion of Phase 1 Clinical Trial of the Company's Proprietary Lead Compound, NVG-291

NervGen Pharma Corp. Announces Executive Changes

NervGen Pharma Corp. announced that it has received CAD 2.321075 million in funding

NervGen Pharma Corp. announced that it has received CAD 2.343036 million in funding

NervGen Pharma Announces First Subject Dosed in Phase 1 Clinical Trial of NVG-291

NervGen Pharma Corp. Provides Regulatory Update on Development Program for NVG-291

Nervgen Pharma Adds Alzheimer's Disease Patient Cohort to Its Phase 1 Clinical Trial Program

NervGen Pharma Corp. Appoints Dr. Randall Kaye to the Company's Board of Directors

NervGen Pharma Corp. Provides an Update on NVG-291

NervGen Pharma Corp. has completed a Composite Units Offering in the amount of CAD 6.45 million.

Financial Position Analysis

Debt to Equity History and Analysis

Balance Sheet

Cash Runway Analysis

Discover healthy companies